Background and importance The use of monoclonal antibodies against the CGRP receptor in the treatment of migraine was approved by the Commission of Pharmacy within the programme of drugs capable of evaluating health outcomes (MERS). An evaluation should be carried out in 3 months with a reduction of at least 50% in the number of episodes.
Aim and objectives The purpose was to evaluate the efficacy and safety of erenumab in the treatment of chronic and episodic migraine
Material and methods This was a retrospective observational study. Patients with chronic or episodic migraine and treated with erenumab (between November 2019 and January 2021) were included.
Demographic and clinical data were collected with the following variables: classification of migraine, number of episodes/month before treatment, days of migraine per month during the treatment and adverse events.
For the collection of the number of migraines and rescues a registration calendar was designed that was delivered to the patient at each visit.
Results 30 patients were included, median age 50.5 years,78.4% women, 66.7% suffered chronic migraine and 33.3% episodic migraine.100% of the patients had tried at least three previous treatments.
In the patients with chronic migraine the mean of days of migraine previous to the treatment were 24.52±4.18 and in the patients with episodic migraine this was 12.5±1.69. After 3 months of treatment 10 (50%) chronic migraine patients and 7 (70%) episodic migraine patients responded to the treatment (at least a 50% reduction compared to the previous number of basal migraines).
The percentage of reduction of the number of migraines/month in responder patients was greater at 6 months (71% of mean reduction for both chronic and episodic migraines) than 3 months after the start (57% of mean reduction for chronic and 63% for episodic migraines).
In relation to the safety of erenumab, 15 patients showed possible adverse effects, the most common being constipation (9 patients, 30%) and skin reactions (4 patients, 15.3%), detecting two cases of serious adverse reactions which forced treatment to be stopped.
Conclusion and relevance The ratio of response to the treatment in both chronic and episodic migraines were greater than 50%which contrasts with the results in the pivotal trials.This can be explained because of the different inclusion criteria. Moreover according to our results we can observe a tendency towards a greater response as the persistence of the treatment is increased. We can conclude that erenumab is an effective and safe drug in the treatment of migraine.
Conflict of interest No conflict of interest